恒瑞医药：RSS0393软膏获批开展临床试验

Group 1 - The core point of the article is that Heng Rui Medicine (600276.SH) announced that its subsidiary, Ruishi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the clinical trial of RSS0393 ointment [1] - RSS0393 ointment is a self-developed product by the company, which contains a PDE4 small molecule inhibitor that can alleviate tissue damage and inflammation by inhibiting PDE4 activity in various cells [1]